Objective: Adropin, a newly identified regulatory protein encoded by Enho gene, suppressed tumor necrosis factor α-induced THP1 monocyte adhesion to human umbilical vein endothelial cells. In addition, inflammation is demonstrated to be involved in the mechanism of atrial fibrillation (AF). Atrial remodeling is correlated with the persistence and progression of AF. Adropin is hypothesized to correlated with AF and atrial remodeling. This study aims to determine the correlation of serum adropin and the presence of AF and remodeling.
| INTRODUC TI ON
Atrial fibrillation (AF) is the most common type of clinical arrhythmia. The incidence of AF is increasing with the prolonged life of the general population. 1 AF results in a great public health cost due to its effect of hemodynamic impairment and increased risk of congestive heart failure, stroke, morbidity, and mortality. 2 The underlying mechanism of AF is still understood. Recent studies focus on the substantial link between inflammation and AF. 3 A variety of inflammatory factors were found to be elevated in AF patients.
Adropin, a newly found regulatory protein, is encoded by Enho gene (energy homeostasis associated) in the brain and liver of mice.
4
Adropin plays an important role in adiposity, insulin resistance, glucose, and lipid metabolism. 5 Sato et al reported that adropin suppressed tumor necrosis factor α-induced THP1 monocyte adhesion to human umbilical vein endothelial cells. 6 This indicates the antiinflammatory role of adropin. As we know, inflammation is a clear mechanism of AF. Therefore, we speculate that adropin may be correlated with AF. However, no previous studies focused on the association of serum adropin and the presence of AF.
The aim of this study was to determine the correlation between serum adropin concentrations and the presence of AF and atrial remodeling.
| MATERIAL S AND ME THODS

| Patients
This study consisted of a population of 344 AF patients. AF patients were diagnosed according to the guidelines established by the European Society of Cardiology in 2010. Patients were enrolled consecutively from the consecutive outpatients who came to the outpatient clinic of our department in Tangdu Hospital from January 2017 to October 2017. Patients were excluded if they had congenital heart disease, valvular heart diseases, acute coronary syndrome, and systemic disease including diabetes, cancer, hypertension, as well as those had a history of infectious, and inflammatory diseases, or antiinflammatory drugs during the past 3 months. These patients were excluded based on the disease history, blood pressure measurements, and laboratory testing results. AF patients were then divided into paroxysmal AF group (n = 122), persistent AF group (n = 130), and permanent AF group (n = 92). The control group included 210 consecutive healthy volunteers who had routine medical checkup in the medical examination center of our hospital from January 2017 to August 2017. The study protocol was approved by the Human Ethics
Review Committee of our hospital and a signed consent form was obtained from each subject. 
| Measurements
| Statistical analysis
The 
| RE SULTS
| Baseline clinical characteristics
Atrial fibrillation patients showed higher systolic blood pressure (SBP), diastolic blood pressure (DBP), triglycerides (TG), LAD, and Creactive protein (CRP), and as well as reduced high-density lipoprotein cholesterol (HDL-C) compared with healthy controls (Table 1 ).
There were no significant differences in other characteristics between the two groups.
| Serum adropin concentrations in AF patients
Atrial fibrillation patients showed significantly reduced serum adropin concentrations compared with healthy controls (Table 1) .
Simple logistic regression analysis indicated that SBP, DBP, TG, HDL, and serum adropin showed a trend toward an association with the presence of AF ( Table 2 ). All these parameters were then entered into a multivariate logistic regression model. Serum adropin concentrations remained to be adversely associated with the presence of AF (OR 0.218, 95% CI 0.15-0.316; P < 0.001) ( Table 2 ). Table 3 presented the characteristics of the subgroups of AF patients.
| Serum adropin concentrations with the subtype of AF
There were no significant differences in the prevalence of hypertension, diabetes, and coronary artery disease, as well as medications targeting hypertension, diabetes, and coronary artery disease between the three subgroups. In AF subgroups, permanent AF patients had reduced serum adropin concentrations than paroxysmal and persistent AF groups (Figure 1 ). Furthermore, decreased serum adropin concentrations were found in persistent AF patients than in paroxysmal AF subjects ( Figure 1 ). Spearman correlation analysis indicated that serum adropin concentrations were inversely correlated with the subtype of AF (r = −0.57, P < 0.001).
| Serum adropin concentrations with other clinical characteristics
Simple linear regression analyses showed that serum adropin in AF patients were negatively correlated with body mass index (BMI) (r = −0.159, P = 0.003), SBP (r = −0.187, P < 0.001), LAD (r = −0.195, P < 0.001), and CRP (r = −0.169, P < 0.001) ( Table 4) . Multiple stepwise regression analysis showed that LAD (β = −0.178, P = 0.001) remained to be inversely associated with serum adropin (Table 4) .
| D ISCUSS I ON
The present study indicated that serum adropin concentrations were decreased in AF patients. Serum adropin was inversely associated with AF subtype. In addition, serum adropin concentrations were negatively correlated with LAD which is a parameter of atrial remodeling. This indicates that adropin is associated with the presence of AF and atrial remodeling.
Inflammation is involved in the pathogenesis of AF. Circulating inflammatory biomarkers were elevated in AF patients. And those inflammatory markers could predict the AF development and AF recurrence after cardioversion or catheter ablation. 3 The atrial interleukin (IL)-17A levels were elevated and correlated with AF. And treatment with anti-IL-17A monoclonal antibody decreased atrial IL-17A levels and significantly suppressed AF development in rats. 7 Adropin suppressed tumor necrosis factor α (TNFα)-induced THP1 monocyte adhesion to human umbilical vein endothelial cells. 6 Adropin also shifted the phenotype to anti-inflammatory M2 rather than pro-inflammatory M1 via peroxisome proliferator-activated receptor γ upregulation during monocyte differentiation into macrophages. 6 Intraperitoneal administration of adropin could decrease mRNA expressions of proinflammatory cytokines TNF-α and IL-6 via regulating the expressions of iNOS in hyperlipidemic rats. 8 All these findings point to the role of adropin in inhibiting inflammation. Our study showed that serum adropin concentrations are inversely correlated with the presence of AF. In addition, CRP is a inflammatory parameter which is demonstrated to be correlated with AF. 9 The current study demonstrated that serum adropin was negatively correlated with CRP. This indicates the possible anti-inflammatory role of adropin. Therefore, it is assumed that adropin may protect against the development of AF by suppressing inflammation. However, this hypothesis should be verified in the future studies. Obesity is considered as a traditional risk factor for AF development. Framingham Heart Study results showed that greater pericardial fat was associated with an increased risk of incident AF. 10 Severe obesity with a BMI of 35 kg/m 2 or higher was demonstrated as a risk factor for postoperative AF after isolated coronary artery bypass grafting. 11 Overweight and obesity were associated with an increased AF risk, whereas weight reduction was independently associated with a reduced risk in a study performed in a population of 18, 290 subjects. 12 Adropin is correlated with obesity mechanism. Adropin is encoded by a gene called Energy Homeostasis Associated (Enho) gene. Liver Enho expression decreased with diet-induced obesity associated with 3 months of fed high-fat diet or with genetically induced obesity, suggesting an association with obesity. 4 Adropin regulated expression of hepatic lipogenic genes and adipose tissue peroxisome proliferatoractivated receptor gamma, a major regulator of lipogenesis. 4 In addition, adropin levels were correlated negatively with BMI.
TA B L E 1 Clinical and biochemical characteristics of the case and control groups
Lower adropin levels were observed in overweighted and obese subjects compared with normal subjects. 13 Adropin concentrations increased after 3 months after Roux-en-Y gastric bypass surgery. 13 All these results suggest that adropin is closely correlated with obesity. Then, adropin is assumed to be involved in the mechanism of AF development and progression through the cross talk with obesity.
Left atrial diameter is utilized as a parameter of assessing atrial remodeling. In patients with sinus rhythm, LAD was shown to predict a future occurrence of AF.
14 A meta-analysis of 22 studies with 3750 patients also showed that increased LAD was associated with an increased risk of the recurrence of AF after radiofrequency ablation. 15 In addition, various results have reported that LAD was a risk factor of cardiovascular events in patients with atrial fibrillation. 16 The current study indicates that serum adropin was correlated with
LAD.
This study has several limitations. First, this is a cross-sectional study. The causative relation must be confirmed by future longitudinal studies. Secondly, the control subjects were recruited from subjects undergoing routine medical checkups in hospital. They are not entirely healthy controls, which may lead to potential bias.
Last, Subjects with hypertension, diabetes, and coronary artery disease were excluded from the control group, while some AF patients were companied with hypertension, diabetes, and coronary artery disease. This may also have some confounding effects on the results.
In conclusion, Serum adropin concentrations are inversely correlated with AF and atrial remodeling.
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